Accessibility Menu
Greenrose logo

Greenrose(OTC) GNRS

Current PriceN/A
Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-100%
1 Month+0%
Greenrose last closing stock price
MetricPriceDate
Last closeUSD 0.002026-06-24
Greenrose stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.002026-06-11
1 month+0%USD 0.002026-04-30
3 month+0%USD 0.002026-03-05
Year to date+0%USD 0.002025-12-31
1 year-100%USD 0.022025-04-02
3 year-100%USD 0.262023-06-23
5 year-100%USD 9.982021-06-25
Since inception-100%USD 9.612020-05-21

Greenrose Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$50.62M

Net Income (TTM)

-$40.10M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 20, 2024

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Greenrose

The Greenrose Holding Company Inc. is a cannabis-focused enterprise based in Amityville, New York. Established in 2014, the company specializes in the cultivation, processing, and distribution of medical cannabis products through its subsidiaries.

Products and Services
  • Manufacturing of medical cannabis products
  • Processing and packaging of cannabis derivatives
  • Distribution of cannabis-related items
Growth Outlook
  • Recent revenue of $7.85 million in Q3 2022 indicates market demand
  • Significant gross profit margin of 33.2% in Q3 2022 shows operational efficiency
  • Expansion potential in the growing cannabis industry supports future growth
Financial Highlights
  • Trailing twelve months (TTM) revenue of $28.5 million reflects strong sales performance
  • Net income margin of 70.6% in TTM indicates effective cost management
  • Operating cash flow of $2.47 million in Q2 2022 demonstrates positive cash generation
AI Generated • Jun 30, 2026

Industry

Pharmaceuticals

CEO

Timothy Bossidy, MBA

Headquarters

Amityville, NY 11701, US

GNRS Financials

Key Financial Metrics (TTM)

Gross Margin

59.05%

Operating Margin

38.74%

Net Income Margin

70.59%

Return on Equity

14.83%

Return on Capital

5.54%

Return on Assets

7.50%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$23.70M

Operating Income

-$4.12M

EBITDA

$7.92M

Operating Cash Flow

$4.44M

Capital Expenditure

-$1.47M

Free Cash Flow

$2.97M

Cash & ST Invst.

$962.00K

Total Debt

$141.89M

Greenrose Performance Analysis

Greenrose annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 25,395,000N/A
Greenrose sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42021-12-31N/A
Q12022-03-31-67.8%
Q22022-06-3012.2%
Q32022-09-30-14.6%
Greenrose annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD 0.99N/A
Greenrose sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42021-12-31103.7%
Q12022-03-31-757.1%
Q22022-06-3031.5%
Q32022-09-30-246.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Currently no data to display.

Quarterly Performance

Name
Q3 2022YOY CHG

Revenue

$7.85M

N/A

Gross Profit

$2.60M

N/A

Gross Margin

33.16%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

91

N/A

Net Income

-$36.04M

-4531.7%

EBITDA

-$10.60M

-985.2%

Quarterly Fundamentals

Name
Q3 2022YOY CHG

Total Cash

$962.00K

+842.4%

Total Debt

$141.89M

+3588.4%

Accounts Receivable

$1.95M

N/A

Inventory

$11.88M

N/A

Long Term Debt

$9.57M

+247.9%

Short Term Debt

$132.32M

+11983.7%

Return on Assets

7.50%

N/A

Return on Invested Capital

9.10%

N/A

Free Cash Flow

-$4.78M

-1054.1%

Operating Cash Flow

-$4.60M

-1009.9%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
INTPIntegrated Pharmaceuticals, Inc.
$0.00+0.00%
MLTOMEDirect Latino, Inc.
$0.00+0.00%
XCRPXcorporeal, Inc.
$0.00+0.00%
BLEVFBeleave Inc.
$0.00+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.76-0.29%
AALAmerican Airlines Group
$13.56-0.08%
SMCISuper Micro Computer
$31.20+0.02%
ONDSOndas
$7.93-0.01%

Questions About GNRS

What is the current price of Greenrose?

Greenrose is trading at N/A per share.

What is the 52-week range for Greenrose?

Over the past 52 weeks, Greenrose has traded between N/A and N/A.

How much debt does Greenrose have?

As of the most recent reporting period, Greenrose reported total debt of $108.66M.

How much cash does Greenrose have on hand?

Greenrose reported $9.06M in cash and cash equivalents in its most recent financial results.

What is Greenrose’s dividend yield?

Greenrose does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.